SeraCare Life Sciences Launches New Diagnostic Control Products for HIV

MILFORD, Mass.--(BUSINESS WIRE)--SeraCare Life Sciences, Inc. (NASDAQ: SRLS) today announced that the Company has launched a set of new products in its diagnostic controls and panels portfolio—the SeraCare HIV-1 Seroconversion Panels. Each of the six panels consists of a set of undiluted plasma samples from a single plasma donor collected over a period of time during the development of detectable specific antibodies to HIV in the blood, or seroconversion, and is highly characterized with enhanced product information. Extensively defined natural patient samples are vital for assay development and regulatory compliance. SeraCare’s HIV seroconversion panels can be used by customers to accelerate development of new test methods, provide a common reference for assay comparison and troubleshoot existing assays.

“These latest new product offerings build on more than 20 years of SeraCare leadership in helping scientists develop diagnostic tools for HIV and support our continued future growth.”

“SeraCare’s HIV product portfolio provides scientists with one of the industry’s most comprehensive historical reference platforms to study this rapidly changing disease,” said Susan Vogt, President and Chief Executive Officer. “These latest new product offerings build on more than 20 years of SeraCare leadership in helping scientists develop diagnostic tools for HIV and support our continued future growth.”

SeraCare HIV-1 Seroconversion Panels are supplied with comprehensive test data vital for assay development and regulatory compliance, including results from twenty U.S. and international test methods for markers of HIV infection such as HIV RNA, 1st to 4th generation screening tests for HIV, confirmatory tests and a rapid discriminatory method. A seroconversion graph of critical data points is also included. The data for SeraCare’s new HIV-1 Seroconversion Panels will be available at www.seracarepanels.com. The enhanced on-line data feature allows SeraCare to provide timely updates whenever new test data are available.

About SeraCare Life Sciences, Inc.:

SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company's innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare's quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry.

Forward-Looking Statements:

This press release contains disclosures that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). All statements regarding our expected future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budget, projected costs or cost savings, capital expenditures, competitive positions, growth opportunities for existing products or products under development, plans and objectives of management for future operations and markets for stock are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these expectations will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, failure to maintain proper inventory levels, availability of financing, reductions or terminations of government or other contracts, interruption in our supply of products or raw materials, actions of SeraCare's competitors and changes in the regulatory environment. Many of these factors are beyond our ability to control or predict.